Utah regulators have given the green light to Nolla Health’s artificial-intelligence platform that evaluates a user’s facial image and generates an acne medication order without a prior in-person visit. The startup’s mobile application captures a selfie, runs the picture through a trained model, and, when confidence thresholds are met, produces a prescription that can be filled at a pharmacy.
The rollout begins as a limited pilot, with physician oversight tapering as enrollment grows. For the first hundred users, two doctors must sign off on every AI-generated order. After the cohort expands to five hundred, physicians will only review prescriptions after they have been issued. Nolla Health said, “physicians review a sample of at least 10% of prescriptions every month,” and they will also examine any case that escalates or shows side effects.
Subscribers pay a monthly fee of $4.99 to access the service, which is limited to adults residing in Utah who present mild-to-moderate acne. The age requirement is 18 years or older, and the platform explicitly excludes severe cases that may need more intensive dermatological care. Users must consent to the AI analysis and agree to the telehealth terms before any prescription is generated.
According to Bloomberg, the algorithm is currently programmed to prescribe eight distinct acne treatments, ranging from topical retinoids to oral antibiotics. The AI selects a regimen based on the visual severity score it assigns, as well as any self-reported medical history entered by the user. The system is designed to stay within FDA-approved indications for each medication, and it logs the decision pathway for later audit.
When the model cannot reach a confidence level sufficient to recommend a specific therapy, the app automatically redirects the user to a human dermatologist for further evaluation. This safety net ensures that ambiguous or complex presentations receive professional attention, aligning the service with existing telemedicine standards. Nolla Health emphasizes that the AI is a decision-support tool rather than a replacement for clinical judgment.
The Utah pilot marks one of the first instances where an AI system independently issues a prescription for a common skin condition, reflecting a broader trend toward algorithm-driven care pathways. Bloomberg’s earlier coverage highlighted the regulatory novelty of the approach, while industry observers note that scaling such models will require ongoing oversight to balance accessibility with patient safety. The outcome of this experiment could influence future state-level telehealth policies.